Table 4 Factors associated with the quality-of-life perception and daily activity impairment at the enrolment
From: Quality of life and work functionality in severe asthma patients: the impact of biological therapies
Features | N | Physical health perception (PCS) | Mental Health perception (MCS) | Daily Activity impairment | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Beta | 95% CI | p-value | Beta | 95% CI | p-value | Beta | 95% CI1 | p-value | ||
Gender | 52 | |||||||||
F | - | - | - | - | - | - | ||||
M | 5.3 | 0.90, 9.8 | 0.019 | 1.4 | -3.8, 6.5 | 0.594 | -18 | -31, -4.7 | 0.009 | |
Age | 52 | -0.18 | -0.37, 0.01 | 0.064 | -0.20 | -0.41, 0.01 | 0.065 | 0.17 | -0.44, 0.77 | 0.581 |
Age at diagnosis | 52 | 0.03 | -0.15, 0.21 | 0.743 | 0.04 | -0.16, 0.24 | 0.688 | -0.24 | -0.80, 0.32 | 0.388 |
BMI | 52 | 0.37 | -0.30, 1.0 | 0.275 | -0.61 | -1.3, 0.13 | 0.102 | 0.86 | -1.2, 2.9 | 0.411 |
Smoke | 52 | -2.8 | -6.5, 0.92 | 0.136 | 1.3 | -2.9, 5.4 | 0.546 | 0.13 | -11, 12 | 0.983 |
Education level | 52 | |||||||||
A | - | - | - | - | - | - | ||||
B | 1.2 | -3.5, 5.8 | 0.615 | 3.3 | -2.0, 8.6 | 0.216 | 2.5 | -13, 18 | 0.747 | |
C | 10 | 4.1, 17 | 0.002 | 9.5 | 2.2, 17 | 0.012 | -4.7 | -26, 17 | 0.663 | |
Atopy | 52 | 0.91 | -4.3, 6.1 | 0.724 | 1.4 | -4.3, 7.1 | 0.619 | -1.9 | -18, 14 | 0.811 |
Nasal polyposis | 52 | 3.6 | -1.0, 8.2 | 0.124 | 0.93 | -4.3, 6.2 | 0.722 | -7.8 | -22, 6.5 | 0.276 |
Drug | 52 | |||||||||
Benralizumab | - | - | - | - | - | - | ||||
Dupilumab | 4.4 | -0.85, 9.6 | 0.099 | 3.2 | -2.7, 9.1 | 0.282 | -8.3 | -25, 8.1 | 0.314 | |
Mepolizumab | -1.0 | -7.2, 5.1 | 0.734 | 0.11 | -6.9, 7.1 | 0.974 | -1.1 | -21, 18 | 0.908 | |
Exacerbations in the previous 12 months | 52 | -1.5 | -4.8, 1.7 | 0.350 | -2.3 | -5.9, 1.2 | 0.193 | 14 | 4.6, 23 | 0.004 |
ACT | 52 | -0.08 | -1.1, 0.92 | 0.867 | 1.5 | 0.43, 2.5 | 0.006 | -2.9 | -5.9, 0.07 | 0.055 |
Spirometric values (M ± SD) | ||||||||||
FEV1 (L) | 52 | 6.4 | 3.2, 9.7 | < 0.001 | 5.7 | 1.9, 9.5 | 0.004 | -16 | -26, -5.3 | 0.004 |
FEV1 (%) | 52 | 0.16 | -0.02, 0.34 | 0.079 | 0.33 | 0.15, 0.51 | < 0.001 | -0.51 | -1.1, 0.03 | 0.064 |
FVC (L) | 52 | 3.6 | 1.6, 5.5 | < 0.001 | 1.7 | -0.71, 4.0 | 0.165 | -9.6 | -16, -3.5 | 0.003 |
FVC% | 52 | 0.14 | -0.06, 0.33 | 0.169 | 0.28 | 0.08, 0.49 | 0.007 | -0.82 | -1.4, -0.26 | 0.005 |
FEV1/FVC | 52 | -0.01 | -0.25, 0.23 | 0.932 | 0.31 | 0.07, 0.56 | 0.013 | 0.11 | -0.62, 0.83 | 0.768 |
FeNO | 52 | 0.17 | -0.27, 0.61 | 0.435 | 0.00 | -0.49, 0.48 | 0.988 | 0.01 | -1.3, 1.4 | 0.992 |
Eosinophils (n/μL) | 52 | 0.00 | -0.01, 0.01 | 0.933 | 0.00 | -0.01, 0.01 | 0.806 | -0.01 | -0.04, 0.03 | 0.763 |
Eosinophils % | 52 | 0.14 | -0.71, 1.0 | 0.737 | -0.25 | -1.2, 0.69 | 0.600 | -0.23 | -2.8, 2.4 | 0.862 |
Employment | 52 | |||||||||
No | - | - | - | - | - | - | ||||
Yes | 3.4 | -1.2, 8.1 | 0.144 | 3.1 | -2.1, 8.3 | 0.233 | -24 | -37, -12 | < 0.001 | |